Agilon Health (AGL) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Agilon Health (AGL) reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of -50.00% [1] - The company generated revenues of $1.44 billion for the quarter ended September 2025, slightly surpassing the Zacks Consensus Estimate by 0.57%, but down from $1.45 billion a year ago [2] - Agilon shares have declined approximately 57.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Agilon has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.56 on revenues of $5.82 billion [7] Market Outlook - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical Services industry, to which Agilon belongs, is ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8]